- Home
- RIGL vs METCB Comparison
RIGL vs METCB Comparison
Compare RIGL & METCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- METCB
- Stock Information
- Founded
- RIGL 1996
- METCB 2015
- Country
- RIGL United States
- METCB United States
- Employees
- RIGL N/A
- METCB N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- METCB Coal Mining
- Sector
- RIGL Health Care
- METCB Energy
- Exchange
- RIGL Nasdaq
- METCB Nasdaq
- Market Cap
- RIGL 335.5M
- METCB 397.7M
- IPO Year
- RIGL 2000
- METCB N/A
- Fundamental
- Price
- RIGL $21.91
- METCB $12.64
- Analyst Decision
- RIGL Buy
- METCB Strong Buy
- Analyst Count
- RIGL 5
- METCB 3
- Target Price
- RIGL $36.40
- METCB $18.33
- AVG Volume (30 Days)
- RIGL 182.1K
- METCB 345.2K
- Earning Date
- RIGL 08-05-2025
- METCB 08-15-2025
- Dividend Yield
- RIGL N/A
- METCB 6.57%
- EPS Growth
- RIGL N/A
- METCB N/A
- EPS
- RIGL 2.08
- METCB N/A
- Revenue
- RIGL $203,077,000.00
- METCB $625,919,000.00
- Revenue This Year
- RIGL $14.41
- METCB N/A
- Revenue Next Year
- RIGL $15.97
- METCB $24.78
- P/E Ratio
- RIGL $10.11
- METCB N/A
- Revenue Growth
- RIGL 70.16
- METCB N/A
- 52 Week Low
- RIGL $8.61
- METCB $6.01
- 52 Week High
- RIGL $29.82
- METCB $16.40
- Technical
- Relative Strength Index (RSI)
- RIGL 66.30
- METCB 54.42
- Support Level
- RIGL $19.51
- METCB $13.57
- Resistance Level
- RIGL $21.41
- METCB $14.52
- Average True Range (ATR)
- RIGL 0.88
- METCB 1.37
- MACD
- RIGL 0.24
- METCB -0.22
- Stochastic Oscillator
- RIGL 96.45
- METCB 27.97
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About METCB Ramaco Resources Inc. Class B
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. Operations are concentrated in the Appalachian basin, with active mines at Elk Creek, Berwind, Knox Creek, and Maben mining complexes.